Recent 8-K filings for SNGX
Highest-materiality recent filing
Soligenix Phase 3 FLASH2 trial of HyBryte for CTCL halted for futility
- Data Monitoring Committee interim efficacy analysis recommended halt; HyBryte failed to show benefit at 18 weeks.
- Company reports ~$5.9M cash; evaluating strategic options including M&A or advancing dusquetide for Behçet's Disease.
-
Soligenix Phase 3 FLASH2 trial of HyBryte for CTCL halted for futility
Data Monitoring Committee interim efficacy analysis recommended halt; HyBryte failed to show benefit at 18 weeks.
-
Soligenix provides pipeline update; FLASH 2 interim analysis in 2Q, cash through 2026
66 patients enrolled in confirmatory Phase 3 FLASH 2 trial for HyBryte in CTCL as of Feb 10; interim analysis expected 2Q 2026.
-
Soligenix enters ATM equity facility with Rodman & Renshaw for up to $3.45M
Up to $3,450,000 of common stock may be sold at market prices through Rodman & Renshaw as sales agent.
-
Soligenix regains Nasdaq minimum stockholders' equity compliance
Received Nasdaq letter on Nov 18, 2025 confirming compliance with minimum $2.5M stockholders' equity requirement.
-
Soligenix closes $7.5M public offering; cash runway extended through 2026
Gross proceeds of ~$7.5M from sale of 5,555,560 units at $1.35/unit, each consisting of one share (or pre-funded warrant) and one warrant.
-
FDA grants Soligenix orphan drug designation for SGX945 in Behçet's Disease
FDA orphan drug designation for dusquetide (SGX945) in Behçet's Disease based on Phase 2a results showing biological efficacy and safety.
-
Soligenix receives Nasdaq deficiency notice for stockholders' equity below $2.5M
Stockholders' equity of $1,828,951 as of June 30, 2025, below Nasdaq's $2.5M minimum.
-
Soligenix SGX945 Phase 2a: 40% improvement in Behçet's ulcers, matching Otezla's 37%
SGX945 achieved 40% improvement vs placebo on primary endpoint at Week 4; apremilast (Otezla) had 37% improvement.
-
Soligenix repays $10M Pontifax loan early, terminates Loan and Security Agreement
Repaid all outstanding obligations under the December 2020 Loan Agreement with Pontifax Medison Finance.
-
Soligenix amends loan deal with Pontifax; conversion price cut to $3.81/$4.23
Conversion price reduced to $3.81 for first 501,648 shares issued after Oct 7, 2024, then $4.23 for subsequent shares.
-
Soligenix enters ATM equity sales agreement for up to $5.8M with AGP
Agreement with A.G.P./Alliance Global Partners allows sale of up to $5.8M in common stock at market prices from time to time.
-
Soligenix regains Nasdaq compliance after reverse stock split, delisting threat resolved
Received Nasdaq letter on July 24, 2024 confirming regained compliance with Minimum Bid Price Rule.
-
Soligenix induces warrant exercise for up to $4.2M, issues new warrants at 150% coverage
Up to 703,125 existing warrants exercised at $6.00/share; gross proceeds up to ~$4.2M.
-
Soligenix to effect 1-for-16 reverse stock split effective June 5, 2024
Reverse stock split at 1-for-16 ratio; effective 4:00 p.m. EST June 5, 2024.
-
Soligenix prices $4.75M public offering of common stock and warrants
Gross proceeds ~$4.75M from unit offering: one share (or pre-funded warrant) and one common warrant per unit.
-
Soligenix gets EMA agreement on confirmatory Phase 3 design for HyBryte in CTCL
EMA agreed on key design for FLASH2: double-blind, placebo-controlled, 18-week continuous treatment.
-
Soligenix receives Nasdaq delisting notice; common stock may be suspended
Nasdaq notified Soligenix on Dec 21, 2023, of failure to meet $1.00 minimum bid price rule.
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event other_material